MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer
Journal Article

Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer

2025
Request Book From Autostore and Choose the Collection Method
Overview
Background This study investigates the clinical significance of myeloid-derived suppressor cells (MDSCs), including polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs) subsets, and regulatory T cells (Tregs) in the peripheral blood of breast cancer patients. Methods Using flow cytometry, we analyzed levels of these immunosuppressive cell populations in 107 breast cancer patients and 33 healthy controls at the Breast Centre of the Fourth Hospital of Hebei Medical University (July-November 2021). Results Levels of MDSCs, PMN-MDSCs, M-MDSCs, and Tregs were significantly elevated in breast cancer patients compared to controls ( P  < 0.05). Furthermore, MDSCs, PMN-MDSCs, and Tregs showed a strong positive correlation with lymph node metastasis ( P  < 0.001). M-MDSCs were also significantly associated, though to a lesser extent ( P  = 0.045). Receiver operating characteristic (ROC) curve analysis revealed high diagnostic value for these cells in breast cancer. Notably, Tregs exhibited the highest individual area under the curve (AUC = 0.766) for detecting lymph node metastasis. Critically, the combined assessment of MDSCs and Tregs significantly enhanced predictive accuracy for lymph node metastasis, yielding a combined AUC exceeding that of any single marker. Conclusion Elevated levels of MDSCs (and their subsets) and Tregs are closely associated with lymph node metastasis in breast cancer. Their combined detection provides an effective predictive tool for lymph node involvement and holds substantial clinical value.